For severe chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), dupilumab showed high therapeutic efficacy in the first 2 years, according to the first long- term, real-life prospective observational cohort study, published in Allergy. Rik Johannes Leonardus van der Lans, MD, and colleagues sought to assess long-term results while tapering dupilumab, with the focus on established therapeutic efficacy. They conducted their research in a single tertiary referral center with add-on dupilumab as primary biological treatment. Participants were biologically-naïve adults with CRSwNP. The study team observed that the mean scores (SD) of all co-primary outcomes improved significantly from baseline (228) to the 48- (214) and 96-week (99) timepoints. Tapering was viable in 79.5% of patients at week 24, 93.7% at week 48, and 95.8% at week 96. “Therapeutic efficacy is principally established within 24 weeks and endures while tapering dupilumab conditional to treatment response and CRS control,” the study authors wrote.
